Does Presbyterian Healthcare Services Cover Metformin?

What Presbyterian Healthcare Services Is and Why It Matters for Metformin Access

Presbyterian Healthcare Services is a not-for-profit integrated health system based in Albuquerque, New Mexico. It operates both a hospital network and Presbyterian Health Plan, a licensed insurer that covers roughly 500,000 New Mexico residents across commercial, Medicare Advantage, and Medicaid (Centennial Care) product lines. Because PHS runs both the clinical and insurance sides of care, its formulary decisions affect a large share of New Mexico's diabetic population directly.

Metformin has been FDA-approved for type 2 diabetes since 1994 and remains the first-line pharmacologic agent recommended in the American Diabetes Association's 2024 Standards of Care. The ADA states: "Metformin, if not contraindicated and if tolerated, is the preferred initial pharmacologic agent for type 2 diabetes" (ADA Standards of Care 2024). Given that clinical consensus, virtually every major insurer, including PHS, places generic metformin on its lowest formulary tier.

Generic metformin immediate-release (IR) is off-patent and manufactured by dozens of suppliers. Its wholesale acquisition cost sits below $0.05 per tablet, which means that even without insurance it rarely costs more than $10 to $15 per month at retail pharmacies. With a PHS Tier 1 copay, the out-of-pocket cost may drop to $0 on some plan designs.

The 2002 Diabetes Prevention Program trial (DPP, N=3,234) demonstrated that metformin 850 mg twice daily reduced progression from pre-diabetes to type 2 diabetes by 31% over 2.8 years compared with placebo (PMID 11832527). That evidence base anchors payer decisions across the country.

How Presbyterian's Formulary Is Structured

Presbyterian Health Plan publishes a drug formulary that divides medications into tiers. Understanding those tiers helps members predict their exact cost before walking up to a pharmacy counter.

Tier 1 includes generic preferred drugs. Tier 2 covers generic non-preferred or low-cost brand drugs. Tier 3 is reserved for brand preferred drugs. Tier 4 holds brand non-preferred drugs, and Tier 5 captures specialty and biologic agents. Most PHS plan designs apply a $0 to $15 copay for Tier 1 and a $30 to $60 copay for Tier 2.

Generic metformin IR (500 mg, 850 mg, 1000 mg tablets) sits at Tier 1 on PHS commercial plans. Generic metformin extended-release (ER, also called metformin XR or Glucophage XR) may sit at Tier 1 or Tier 2 depending on which generic manufacturer's product PHS has contracted. Brand-name Glucophage, Fortamet, Glumetza, and Riomet are generally placed at Tier 3 or Tier 4, and PHS often requires step therapy through the generic before it will pay for the brand.

Formularies change on January 1 of each plan year. Before filling any prescription, members should verify current tier placement by logging into the PHS member portal at presbyterianhealthplan.org or calling member services at 1-888-977-2345.

Does PHS Require Prior Authorization for Metformin?

For generic metformin used to treat diagnosed type 2 diabetes, PHS does not require prior authorization on most plan designs. The prescriber writes a standard prescription, the pharmacy processes it, and the member pays the Tier 1 copay.

Prior authorization (PA) may be required in two specific situations. First, if a prescriber orders a brand-name ER formulation without first documenting a trial of generic metformin ER, PHS may deny the claim and request a step-therapy override. Second, if metformin is being prescribed for an off-label indication, such as pre-diabetes prevention, polycystic ovary syndrome (PCOS), or investigational longevity protocols, PHS may request a Letter of Medical Necessity (LMN) documenting clinical rationale.

For PCOS, there is reasonable published evidence. A 2012 Cochrane review found metformin improved ovulation rates compared with placebo in women with PCOS (Cochrane Database Syst Rev, PMID 22336789). Prescribers appealing a PA denial for PCOS should cite this literature in the LMN and include the patient's diagnosis codes (ICD-10 E28.2).

The PA process for off-label use typically takes 3 to 5 business days for a standard review. If the patient has a documented urgent need, providers can request an expedited 72-hour review under New Mexico state insurance regulations.

Metformin for Pre-Diabetes: Will Presbyterian Cover It?

Pre-diabetes coverage is the gray zone for most insurers, including PHS. The ADA's 2024 guidelines recommend considering metformin for adults with pre-diabetes who are at high risk of progression, particularly those with BMI <35, age <60, or a history of gestational diabetes (ADA Standards of Care 2024, Section 3).

Whether PHS will cover metformin for pre-diabetes depends on the specific plan design and whether the member's plan uses ICD-10 code R73.09 (other abnormal glucose) or E11.x (type 2 diabetes) on the claim. Some PHS Medicaid Centennial Care plans have a broader prevention mandate under New Mexico's Medicaid contract and may cover metformin for pre-diabetes under a prevention benefit.

The DPP Outcomes Study followed participants for a median of 15 years after the original trial and found that metformin use was associated with a 17% reduction in diabetes incidence even after accounting for lifestyle changes (PMID 25948294). Presenting this long-term data in an LMN strengthens the medical necessity argument considerably.

Practically, prescribers at PHS-affiliated clinics have the best success by documenting: (1) fasting glucose 100 to 125 mg/dL or HbA1c 5.7% to 6.4% on two separate tests, (2) failure or ineligibility for intensive lifestyle intervention, and (3) at least one high-risk feature such as obesity, family history, or prior gestational diabetes.

Metformin for Longevity and Aging: The Coverage Question

The interest in metformin as an anti-aging agent has grown substantially since the TAME (Targeting Aging with Metformin) trial began enrollment. TAME is an NIH-funded, double-blind, placebo-controlled trial targeting approximately 3,000 adults ages 65 to 79 without diabetes, testing whether metformin 1 to 500 mg/day delays the onset of age-related diseases (ClinicalTrials.gov NCT04994561). Results are not yet published as of mid-2025.

PHS, like virtually every other U.S. insurer, does not cover metformin for a longevity indication because no FDA approval exists for that use and the TAME trial data are not yet available. Claims submitted with ICD-10 code Z13.88 (encounter for screening, disorder due to exposure to contaminants) or similar "wellness" codes are routinely denied.

Patients who want metformin for longevity purposes and do not have diabetes or pre-diabetes will generally pay out of pocket. At GoodRx pricing, generic metformin 500 mg, 60 tablets (a one-month supply of 1 to 000 mg/day) costs approximately $5 to $12 at most New Mexico pharmacies, making out-of-pocket access financially reasonable for most patients.

The HealthRX Longevity Coverage Framework below outlines how to approach an insurer like PHS when requesting metformin coverage outside of a type 2 diabetes diagnosis.

HealthRX Longevity Coverage Framework: Stepwise Approach for Non-Diabetic Metformin Requests

1. Document a recognized ICD-10 code when one applies (E11.x for T2DM, E11.65 for pre-diabetes risk, E28.2 for PCOS, O24.419 for gestational diabetes history).
2. Confirm the prescriber has noted two abnormal metabolic lab values in the chart within the past 12 months.
3. Request a Tier 1 generic prescription to minimize the formulary review burden on the plan.
4. If denied, file an appeal within 30 calendar days using the TAME trial protocol and ADA pre-diabetes guidelines as supporting literature.
5. While the appeal is pending, use a GoodRx coupon at a local pharmacy, since the out-of-pocket cost for generic metformin rarely exceeds $12 per month.
6. If the appeal is denied a second time, escalate to the New Mexico Office of the Superintendent of Insurance (OSI) for external review.

Metformin Dosing: What PHS Will Cover

Coverage limits sometimes tie to dose. Understanding the clinically approved dose range helps members confirm that their prescription will process without issue.

The FDA-approved adult dose of metformin IR is 500 mg twice daily to start, titrated to a maximum of 2 to 550 mg per day in two or three divided doses. The ER formulation is typically dosed once daily with the evening meal, starting at 500 mg to 1 to 000 mg and going up to 2 to 000 mg per day. Doses above 2 to 000 mg/day for ER are generally not covered by PHS without additional documentation because the FDA label caps the ER form at 2 to 000 mg and clinical benefit beyond that threshold is limited.

The landmark UKPDS 34 trial (N=1,704 overweight patients with newly diagnosed type 2 diabetes) showed that metformin reduced any diabetes-related endpoint by 32% versus conventional treatment (P<0.002) and reduced all-cause mortality by 36% (BMJ 1998, PMID 9742977). This trial established metformin as the preferred agent in overweight patients and underpins every major guideline's first-line recommendation.

Quantity limits on most PHS plans allow up to a 90-day supply per fill at a preferred mail-order pharmacy, which can reduce per-unit cost further. A 90-day supply of generic metformin 1 to 000 mg twice daily (180 tablets of 1 to 000 mg) typically processes at the Tier 1 copay.

How Metformin Interacts With Other Drugs in a PHS Formulary

Patients prescribed metformin frequently take other medications, and understanding coverage for those combinations matters.

Metformin combined with a sodium-glucose cotransporter-2 (SGLT-2) inhibitor such as empagliflozin (Jardiance) or dapagliflozin (Farxiga) is a common regimen. Both SGLT-2 inhibitors sit at Tier 3 or Tier 4 on PHS commercial formularies and require prior authorization. The 2023 ADA/EASD consensus statement recommends adding an SGLT-2 inhibitor to metformin in patients with established cardiovascular disease or high cardiovascular risk, citing the EMPA-REG OUTCOME trial in which empagliflozin reduced cardiovascular death by 38% compared with placebo (NEJM 2015, PMID 26378978). Prescribers can use that trial data in a PA request to PHS for empagliflozin when metformin alone is insufficient.

GLP-1 receptor agonists such as semaglutide (Ozempic) are also frequently combined with metformin. These agents sit at Tier 4 or Tier 5 on PHS plans and almost universally require PA plus documentation of HbA1c above 7.5% and BMI >30 (or BMI >27 with a weight-related comorbidity). Coverage for the combination of metformin plus a GLP-1 agonist is generally approved when the prescriber documents inadequate glycemic control on metformin monotherapy.

Practical Steps to Confirm and Use Your PHS Metformin Benefit

Confirming coverage before the pharmacy visit saves time and avoids surprise costs at the counter. Here is a concrete sequence.

Step 1. Pull your current formulary. Log into your PHS member account at phs.org, manage to "Pharmacy Benefits," and search for "metformin." The search returns the current tier, any coverage restrictions, and the member copay.

Step 2. Verify the strength and formulation. Confirm whether your prescriber is ordering IR or ER, and at what strength. Generic IR at all available strengths (500 mg, 850 mg, 1 to 000 mg) is almost uniformly Tier 1. ER formulations may vary.

Step 3. Ask the prescriber to include the diagnosis code. The claim must carry a covered ICD-10 code. For type 2 diabetes, E11.65 (with hyperglycemia) or E11.9 (without complications) are standard. Verify with your prescriber's office that the code sent to the pharmacy matches your documented diagnosis.

Step 4. Use in-network preferred pharmacies. PHS has a preferred pharmacy network that includes Walgreens, Walmart Pharmacy, and independent New Mexico pharmacies enrolled in PHS's network. Using a preferred pharmacy applies the lower Tier 1 copay rather than the out-of-network cost.

Step 5. Request a 90-day supply. PHS's mail-order pharmacy (Express Scripts for most commercial plans) dispenses 90-day supplies at two times the 30-day copay, effectively giving the third month at no additional charge on some plan designs.

Step 6. Appeal if denied. If a claim is denied, request the Explanation of Benefits (EOB) and file an appeal within 30 days. Include the prescriber's clinical notes, relevant lab values (HbA1c, fasting glucose), and at least one published guideline citation.

Metformin Safety Considerations That May Affect Coverage Decisions

PHS may add coverage restrictions for specific patient populations based on safety labeling.

Metformin carries an FDA black box warning for lactic acidosis, a rare but serious metabolic complication. The FDA label contraindicates use in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m² and recommends caution for eGFR 30 to 45 mL/min/1.73 m² (FDA label, NDA 020357). PHS pharmacy benefit management software may flag a prescription for a patient with documented CKD Stage 4 or 5 and require a pharmacist override with physician acknowledgment of the risk.

Vitamin B12 deficiency is a recognized long-term side effect of metformin. The 2024 ADA Standards of Care recommend periodic B12 level monitoring in patients on long-term metformin, particularly those with peripheral neuropathy or anemia (ADA 2024, Section 9). B12 monitoring labs are generally covered by PHS under preventive or chronic disease management benefits.

Iodinated contrast media administered for imaging studies can increase the risk of contrast-induced nephropathy in patients on metformin. The American College of Radiology recommends withholding metformin for 48 hours after contrast administration in patients with eGFR <60 mL/min/1.73 m². Prescribers at PHS-affiliated imaging centers typically manage this automatically, but patients should inform radiology staff of all current medications.

New Mexico Medicaid (Centennial Care) and Metformin

Patients covered under PHS's Centennial Care Medicaid managed care plan have a separate formulary governed by the New Mexico Medicaid Drug Formulary. Generic metformin is included on the New Mexico Medicaid Preferred Drug List (PDL) as a Preferred Agent for type 2 diabetes, which means it requires no PA and carries no copay for most Medicaid-eligible members.

New Mexico Medicaid covers metformin for diabetes prevention in high-risk individuals who are enrolled in the CDC-recognized National Diabetes Prevention Program (National DPP). The CDC's Diabetes Prevention Recognition Program lists approved DPP providers in New Mexico (CDC DPP Provider Search), and PHS Centennial Care members who complete the 16-core sessions may qualify for continued metformin coverage under a prevention benefit code.

The DPPOS (Diabetes Prevention Program Outcomes Study) reported that participants originally randomized to metformin had a 49% lower rate of diabetes if they had gestational diabetes history compared with the lifestyle intervention group (PMID 25948294). This subgroup finding supports a targeted coverage policy for Medicaid members with a history of gestational diabetes.

Medicare Advantage Through PHS and Metformin Coverage

PHS offers Medicare Advantage (MA) plans in New Mexico under the Presbyterian Medicare Advantage brand. Under Part D (the outpatient prescription drug benefit embedded in most MA plans), generic metformin is categorized as a covered Part D drug. The Centers for Medicare & Medicaid Services (CMS) requires that Part D plans cover drugs on the six protected drug classes and strongly incentivizes coverage of diabetes first-line agents.

Generic metformin on PHS Medicare Advantage Part D formularies sits at Tier 1 with a $0 to $5 copay during the initial coverage phase. After meeting the Part D deductible (if applicable), members pay the Tier 1 cost-sharing for each fill. CMS's 2024 Low Income Subsidy (Extra Help) program may reduce this copay to $0 for eligible low-income Medicare beneficiaries.

One important nuance: metformin is not considered a protected class drug under Part D, which means PHS's Medicare plan could theoretically remove it from the formulary mid-year with 60 days' notice. In practice, this almost never happens given the drug's cost profile and guideline status, but members should check their Annual Notice of Change (ANOC) each fall.